Make your money go further for just 25p per day

IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme

02/06/2010 · IS Pharma (ISPH) 

The company, which provides specialist pharmaceuticals and equipment in core areas such as Oncology and Neurology saw revenue up 17% to £14.2m (2009: £12.2m).

This includes £0.7m from the Volplex and Isoplex Distribution and Sale agreement. Product sales were up 19% to £13.4m (2009: £11.2m) and pre-tax profit up 30% to £2.6m (2009: £2.0m) post exceptional items of £0.4m (2009: £0.6m). Basic earnings per share were 7.3p (2009: 9.1p).

Consensus estimates were for pre-tax profit of £2.98m and eps of 8.23p, however, there was a big spread between the 2 analysts covering this one (6.7p…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on IS Pharma

IS Pharma plc – placing at a premium gives confidence and we get a dividend as well

06/10/2010 · Company Insights
The speciality pharmaceutical company has announced that it has raised £3.6m at 77p per share with…

IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme

02/06/2010 · Company Insights
The company, which provides specialist pharmaceuticals and equipment in core areas such as Oncology and Neurology…

More Company Insights

Elderly challenges | Demotion | Australian boost

21/11/2024 · Churchill China · CVS Group · Renold · Tracsis

Bonkers Bargains: poised to recover with a new CEO

20/11/2024 · James Cropper

Improving returns | Questionable business models

Sign-up to our free email updates

SIGN UP